You may want to read the article about the Bushs’ and Crohn’s disease.
You know the name Casey Abrams from the tenth and most recent season of American Idol. The multi-talented 20-year old wowed the judges and America with his jazz renditions.
Abrams suffers from ulcerative colitis, an inflammatory bowel disease which causes ulceration and inflammation of the colon, and that occasionally requires blood transfusions. This disease is also called inflammatory bowel disease (IBD), ileitis, enteritis, or sometimes Crohn’s disease, which is another type of IBD.
Casey was hospitalized while on American Idol due to IBD. Ulcerative colitis can occur in people of any age, but it usually starts between the ages of 15 and 30. Sometimes it will affect people between 50 and 70 but that is not common. It affects men and women equally and appears to run in families. A higher incidence of ulcerative colitis is seen in Caucasian people and people of Jewish descent. About 1.4 million Americans are living with ulcerated colitis or Crohn’s disease.
Symptoms include anemia, rectal bleeding, joint pain, skin lesions, weight loss, and fatigue.
Casey has teamed up with the Crohn’s and Colitis Foundation of America (CCFA) on IBD Icons www.IBDIcons.com to inspire people living with IBD to pursue their dreams. Through the campaign, people living with IBD will have the opportunity to share their stories of success for a chance to win the title of IBD Icon and a trip to see Casey perform at the Zappos.com Rock ‘n’ Roll Las Vegas Marathon & ½ Marathon to benefit the CCFA. Casey’s message is to encourage people to ask for help early on in spite of young people often being embarrassed by some of the symptoms.
Six finalists will be chosen, then the public can vote for the candidate they find most inspiring. Two winners – one with ulcerated colitis and one with Crohn’s will be voted the 2011 IBD Icons. For every vote cast, Janssen Biotech, Inc. will donate $1 to the CCFA for IBD research and education.
The voting starts September 29, 2011.
You can read more here.